GlassScriptPhysician profile
Matthew Kliethermes
NPI 1417303363
$2,303.89
in general payments reported to CMS, 2019-2025
18 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $42.56 · 2021: $278 · 2022: $416 · 2023: $373 · 2024: $503 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,250.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $719.69 | 2019-2025 | Rocklatan, Clareon, Acrysof Iq Panoptix Uv Iol |
| Bausch & Lomb Americas INC. | $274.05 | 2023-2024 | Vyzulta, Xiidra, Miebo |
| Aerie Pharmaceuticals, INC. | $176.25 | 2019-2021 | |
| Amgen INC. | $165.58 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $147.65 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $121.58 | 2024-2025 | Tecnis Iol, Whitestar Signature Pro, Tecnis Iol |
| Apellis Pharmaceuticals, INC. | $107.09 | 2024-2025 | Syfovre |
| Rxsight INC | $98.85 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Genentech USA, INC. | $88.72 | 2022 | |
| Allergan, INC. | $78.33 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $69.63 | 2022-2025 | Acthar |
| Tarsus Pharmaceuticals, INC. | $63.18 | 2024-2025 | Xdemvy |
| Rayner Intraocular Lenses Limited | $46.96 | 2023 | Rayone Aspheric, Omidria, Rayone Emv |
| Sight Sciences, INC. | $39.81 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Thea Pharma INC. | $32.14 | 2023-2025 | Iyuzeh |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $27.08 | 2024 | |
| Astellas Pharma US INC | $25.86 | 2025 | Izervay |
| Sun Pharmaceutical Industries INC. | $21.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Kliethermes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.